ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 235 filers reported holding ROYALTY PHARMA PLC in Q2 2021. The put-call ratio across all filers is 1.38 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $23,849,996 | +3066.1% | 904,436 | +3546.3% | 0.02% | +2300.0% |
| Q1 2024 | $753,297 | -85.6% | 24,804 | -86.7% | 0.00% | -83.3% |
| Q4 2023 | $5,230,237 | +1189.3% | 186,196 | +1145.7% | 0.01% | – |
| Q3 2023 | $405,661 | +7.6% | 14,947 | +42.9% | 0.00% | – |
| Q1 2023 | $376,945 | -92.6% | 10,462 | -91.9% | 0.00% | -100.0% |
| Q4 2022 | $5,083,050 | -14.2% | 128,619 | -12.7% | 0.01% | -25.0% |
| Q3 2022 | $5,921,000 | -54.9% | 147,370 | -52.8% | 0.01% | -50.0% |
| Q2 2022 | $13,121,000 | +8.7% | 312,118 | +0.7% | 0.02% | +33.3% |
| Q1 2022 | $12,073,000 | -38.5% | 309,882 | -37.1% | 0.01% | -36.8% |
| Q4 2021 | $19,638,000 | +19.5% | 492,794 | +8.3% | 0.02% | +5.6% |
| Q3 2021 | $16,440,000 | -17.6% | 454,894 | -6.6% | 0.02% | -18.2% |
| Q2 2021 | $19,963,000 | -15.2% | 487,022 | -9.8% | 0.02% | -24.1% |
| Q1 2021 | $23,551,000 | -22.5% | 539,906 | -11.1% | 0.03% | -27.5% |
| Q4 2020 | $30,386,000 | – | 607,115 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $263,446,000 | 59.92% |
| Memorial Sloan Kettering Cancer Center | 1,128,255 | $43,957,000 | 50.90% |
| Vantage Consulting Group Inc | 2,727,854 | $106,277,000 | 41.47% |
| Indie Asset Partners, LLC | 756,874 | $29,488,000 | 22.15% |
| Overbrook Management Corp | 723,250 | $28,178,000 | 6.25% |
| Brown University | 621,759 | $24,224,000 | 5.93% |
| Geo Capital Gestora de Recursos Ltd | 200,692 | $8,527,000 | 3.82% |
| Lagoda Investment Management, L.P. | 141,560 | $5,515,000 | 2.97% |
| Greytown Advisors Inc. | 131,143 | $5,109,000 | 2.47% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 2,025,610 | $78,918,000 | 2.41% |